[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-childhood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-childhood":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,78,122,143,176,200,237,264,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641572","infant-rsv-immunity-study-100641572",false,"NCT07653347","Infant RSV Immunity Study","Understanding the Impact of Early-life RSV Infections on Infant Immunity and Long-term Health","IRIS","Inclusion Criteria:\n\nBirthing parent\u002Fchild pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.\n\nExclusion Criteria:\n\nSevere pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \\\u003C 35 weeks of gestation, or with chronic medical conditions).",true,"ALL","6 Months",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\\\u003C4 months) versus late (\\>6-9 months) in infancy.",[26,27],"Respiratory Synctial Virus","Asthma Childhood",[29,30,31,32],"cohort study","Immune response","infants","season of birth","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":37},"2026-01-15",{"date":41,"type":22},"2029-12-01",{"name":43,"class":44},"University of British Columbia","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100642620","active-airways-for-children-and-young-people-with-asthma-100642620","NCT07643753","Active Airways for Children and Young People With Asthma","The Feasibility of an Exercise and Asthma Educational Programme 'Active Airways' on Health Outcomes in Children and Young People With Asthma With All Severities","Inclusion Criteria:\n\nWilling and able to consent to participate in the trial\n\nAble to understand written and spoken English\n\nA diagnosis of Mild to Moderate Asthma or Severe Asthma based on the European Respiratory Society (ERS)\u002F American Thoracic Society (ATS) consensus statement on Severe Asthma\n\nAble to participate in a formal exercise programme\n\nAged 10-17 years\n\nAble to engage in focus groups\n\nApproximately 130cm tall (to be able to complete cardiopulmonary exercise testing (CPET))\n\nExclusion Criteria:\n\nSelf-reported uncontrolled severe exercise-induced breathlessness\n\nRequired a course of antibiotics or oral corticosteroids within the 4 weeks prior to the study commencing\n\nChildren with severe co-morbidities that will not allow them to participate in an exercise programme e.g. Severe neuromuscular disorders, recent fractures or surgeries, cognitive or behavioural conditions.\n\nParticipant is unable or unwilling, in the opinion of the investigator, to give informed consent","10 Years","17 Years",{"count":56,"type":22},60,"INTERVENTIONAL",[59],"NA","What is this study about? The investigators want to see if exercise and education sessions can help children and young people (aged 10-17) with asthma, manage the participants asthma better.\n\nThe investigators will place participants that are recruited to this study into one of three groups by a computer (randomly):\n\nGroup 1:\n\nUsual Care: Continue with normal asthma treatment.\n\nGroup 2:\n\nEducation: Usual care + a 45-minute online asthma education class once a week.\n\nGroup 3:\n\nExercise \\& Education: Usual care + 3 exercise sessions a week and asthma education classes.",[27,62,63],"Exercise","Children",[65,66,67,68],"asthma","children","exercise","physical activity","NOT_YET_RECRUITING","2026-06-09",{"date":34,"type":37},{"date":73,"type":22},"2026-07",{"date":75,"type":22},"2030-09",{"name":77,"class":44},"University of Leicester",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":57,"phases":90,"briefSummary":91,"conditions":92,"keywords":102,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100635983","the-root-study-scaling-the-standard-of-care-plus-obstetric-nutrition-model-to-optimize-maternal-and-infant-health-100635983","NCT07559773","The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Model to Optimize Maternal and Infant Health","The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Integrated Model to Optimize Maternal and Infant Health: a Prospective Interventional Study: Resilient Outcomes Through OB-Nutrition Team Care (ROOT)","ROOT","Inclusion Criteria:\n\n* Pregnant women receiving care at NH Triad OB\u002FGYN\n* ≤20 weeks gestational age at enrollment\n* Age ≥ 18 years (\\\u003C18 years requires parental consent)\n* Ability to provide informed consent\n* Access to smart phone\u002Finternet for digital platform use\n\nExclusion Criteria:\n\n* \\> 20 weeks gestational age\n* High-risk pregnancies requiring specialized care beyond study scope\n* Inability to participate in digital health platform\n* Cognitive impairment preventing informed consent","FEMALE","18 Years",{"count":89,"type":22},500,[59],"The 'Standard of Care Plus' ('PLUS') model in the ROOT Study consists of analyzing select micronutrient and gene variants of pregnant females to construct trimester-specific and personalized nutrition and lifestyle recommendations in collaboration with in-person standard obstetric care (SOC).\n\nIn 2014, the investigators demonstrated statistically significant reductions in adverse maternal and infant outcomes using the 'PLUS' model compared to SOC alone. Further study in a 50% Medicaid Oregon 'PLUS' cohort (N=387) demonstrated association with highly significant risk reductions in all primary outcomes (p-value \\\u003C0.001): preterm birth: relative risk (RR) = 0.238 (4.2x less likely), hypertensive disorders of pregnancy: RR = 0.229 (4.4x less likely), gestational diabetes: RR = 0.071 (14x less likely), small for gestational age: RR = 0.252 (4x less likely), and large for gestational age: RR = 0.357 (2.8x less likely). A 100% Medicaid and ethnically diverse Nevada 'PLUS' cohort showed similar trends in all outcomes that were not statistically significant because of small sample size.\n\nStructured as a prospective interventional study, the study evaluates whether the 'PLUS' model can achieve similar outcome improvements within the Novant Health (NH) system in North Carolina. The study will assess both clinical outcomes and digital nutrition platform performance within the existing healthcare infrastructure.\n\nThe primary hypothesis of the ROOT study is that collaborative implementation of the 'PLUS' nutritional care model at NH Triad Obstetrics\u002FGynecology (OB\u002FGYN) Clinic will be associated with reduced maternal and infant adverse outcome rates when compared to historical regional and NH system outcomes in those who received SOC alone.\n\nThe secondary hypothesis of the ROOT Study is that the 'PLUS' model applied during pregnancy will be associated with reduced pediatric adverse outcomes. The 'PLUS' offspring that remain in the NH system will be observed longitudinally over 5 years with chart review at birth through 2 weeks of age, and at 1, 3, and 5 years of life. The outcomes assessed include neonatal intensive care unit (NICU) admission in the first two weeks of life, atopic dermatitis, eczema, asthma, allergies, otitis media, obesity, and autism. The 'PLUS' adverse outcome rates will be compared to adverse outcome rates in children born regionally and nationally under SOC alone.\n\nParticipant compliance with the 'PLUS' model, and participant and nutritionist access to the digital health platform will be studied during each trimester of use, as well as in the postpartum time period. The exploratory hypothesis is that the digital platform will not affect access, compliance, and rates of maternal and neonatal adverse outcomes.",[93,94,95,96,97,27,98,99,100,101],"Preterm Birth","Preeclampsia","Gestational Diabetes Mellitus (GDM)","Small for Gestational Age (SGA)","Large for Gestational Age (LGA)","Atopic Dermatitis","Autism","Otitis Media Recurrent","Obesity",[103,104,105,106,107,108,109,110,111,112],"adverse pregnancy outcomes","prevention","personalized nutrition","nutrigenomics","adverse neonatal outcomes","childhood asthma","childhood allergy","autism","childhood obesity","recurrent otitis media","2026-04-27",{"date":115,"type":37},"2026-04-30",{"date":117,"type":22},"2026-08",{"date":119,"type":22},"2033-12",{"name":121,"class":44},"GrowBaby Life Project",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":18,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":57,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100635920","application-construction-and-effect-evaluation-of-family-empowered-pulmonary-rehabilitation-in-school-age-children-with-asthma-100635920","NCT07558954","Application Construction and Effect Evaluation of Family-empowered Pulmonary Rehabilitation in School-age Children With Asthma","Inclusion Criteria:(All must be met)\n\n* School-aged children aged 6 to 12 years.\n* Meet the diagnostic criteria for asthma according to the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2025 Edition).\n* Received regular inhaled asthma medications for at least 3 months, with moderate or better medication adherence (score ≥6 on the Morisky Medication Adherence Scale).\n* Pulmonary function test shows obstructive ventilatory dysfunction or small airway dysfunction.\n* The primary caregiver has good communication and literacy skills, can use smartphone applications (e.g., WeChat) proficiently, and is willing to participate in the study.\n* Written informed consent has been obtained from the participant and their legal guardian.\n\nExclusion Criteria:(Any one leads to exclusion)\n\n* Children in acute asthma exacerbation.\n* Presence of other severe chronic diseases (e.g., congenital heart disease, neuromuscular disease, immunodeficiency disease, etc.).\n* Children with mental or psychological disorders who cannot cooperate.\n* Other conditions judged by the investigator to be unsuitable for participation in this study.","6 Years","12 Years",{"count":131,"type":22},92,[59],"Study Purpose: To develop a pulmonary rehabilitation intervention program suitable for school-age children with asthma, and to evaluate its effectiveness in improving asthma control in children through a prospective randomized controlled trial.\n\nStudy Methods: This is a single-center, prospective, randomized, open-label, parallel-controlled trial. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria, together with their families, will be randomly assigned in a 1:1 ratio to either the intervention group (family-empowered pulmonary rehabilitation intervention) or the control group (conventional pulmonary rehabilitation care) after signing the informed consent form.\n\nBoth groups will receive a 12-week core intervention period, with follow-up assessments conducted at baseline, end of intervention (12 weeks), and at 24 and 48 weeks after intervention.",[27],"2026-04-26",{"date":115,"type":37},{"date":138,"type":22},"2026-05-01",{"date":140,"type":22},"2027-12-31",{"name":142,"class":44},"The Children's Hospital of Zhejiang University School of Medicine",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":18,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":57,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":45},"100631405","advancing-diagnosis-and-treatment-of-pediatric-asthma-100631405","NCT07500246","Advancing Diagnosis and Treatment of Pediatric Asthma","Advancing Diagnosis and Treatment of Pediatric Asthma by Deep Immunophenotyping and Evaluation of Two Spacer Devices for Inhaled Corticosteroid Administration","Care4Asthma","Inclusion Criteria:\n\n* Patient aged between 5-16 years, male or female\n* Physician diagnosis of asthma requiring a controller treatment with ICS or ICS\u002FLong-acting beta-agonists (LABA) via MDI\n* Partly controlled or uncontrolled asthma based on GINA criteria and definitions\n* Informed consent signed by legally authorized representatives (LAR) and assent from young patient (only applicable for children ≥ 10 years)\n\nExclusion Criteria:\n\n* Patients with severe asthma exacerbation treated with systemic corticosteroids within the last 2 weeks or patients with active respiratory tract infection\n* Diagnosis of underlying chronic lung disease other than asthma (e.g., BPCO\u002Fcystic fibrosis etc.)\n* Severe asthma based on GINA definitions\n* Severe underlying disorders ((severe congenital heart disease, oncologic patients) (non-exhaustive list, left to the evaluation of the PI))\n* Immune deficiency or under immunosuppressive treatments\n* In receipt of immunotherapy (only for participants in Luxembourg donating samples for biomarker research)\n* Patients with neurological diseases \u002F impaired cognitive disorder\n* Siblings of patients already included in the study","5 Years","16 Years",{"count":154,"type":22},208,[59],"Asthma is one of the most common chronic diseases in children, and treatment success often depends on proper inhaler use and consistent medication adherence. Exposure to allergens and pollutants can also impact treatment response and asthma control. Moreover, there is a growing need for non-invasive biomarkers to support better diagnosis and personalized care. The goal of this clinical trial is to investigate if a new digital inhaler can improve inhalation technique and treatment adherence in children aged 5 to 16 years old, with partly controlled or uncontrolled asthma requiring treatment with inhaled corticosteroids. The main questions it aims to answer are:\n\n* Does the use of a digital inhaler improve adherence to inhaled corticosteroids and asthma control in children?\n* Which biomarkers could support diagnosis and help predict treatment responses in children with asthma?\n* How do environmental factors influence asthma control and treatment outcomes?\n\nResearchers will compare adherence to inhaled corticosteroid therapy between children using a new digital inhaler (Whizz spacer) and those using a standard, non-digital inhaler (AeroChamber Plus® Flow-Vu®) to see if the digital inhaler improves treatment administration and asthma control. They will quantify inflammatory markers in biological samples from asthmatic children and children without respiratory disease, to find biomarkers linked to disease and treatment response.\n\nParticipants will:\n\n* Use the Whizz spacer or the AeroChamber Plus® Flow-Vu® during 12 weeks for corticosteroid inhalation, and complete daily a study diary to follow treatment administration.\n* Complete asthma control and quality of life questionnaires and have an evaluation of asthma control through GINA score at baseline, 6 and 12 weeks.\n* Undergo spirometry tests and FENO measurements at baseline and 12 weeks.\n* Give biological samples at baseline and 12 weeks.\n* Collect children's bedroom dust samples at baseline.\n* Wear a bracelet for 7 days at baseline and 12 weeks to monitor physical activity.",[27,158,159],"Asthma","Inhalation Spacers",[158,161,162,163,164,165],"Child","Immunophenotyping","Environmental exposure","Inhalation spacers","Allergy and asthma","2026-03-24",{"date":168,"type":37},"2026-03-30",{"date":170,"type":37},"2026-01-02",{"date":172,"type":22},"2027-08",{"name":174,"class":175},"Luxembourg Institute of Health","OTHER_GOV",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":18,"minAge":128,"maxAge":54,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":181,"conditions":184,"keywords":188,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100624679","asmact-study-on-management-of-bronchial-asthma-100624679","NCT07412769","ASMact: Study on Management of Bronchial Asthma","Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.","Inclusion Criteria:\n\n* Age between 6 and 17 years\n* Presentation to the emergency department with a diagnosis of acute asthma exacerbation\n* Evaluation in the emergency department of one of the participating centers during the study periods\n\nExclusion Criteria:\n\n* Age \\\u003C 6 years or \\> 17 years\n* Diagnosis other than acute asthma exacerbation\n* Incomplete or missing clinical data\n* Patients transferred from other hospitals already treated for the same episode\n* history of allergy to any drugs used in the protocol",{"count":89,"type":22},[185,27,186,187],"Asthma Acute","Asthma in Children","Asthma Crisis",[189],"asthma attack, exacerbation,","2026-02-13",{"date":192,"type":37},"2026-02-17",{"date":194,"type":37},"2025-11-05",{"date":196,"type":22},"2026-06-30",{"name":198,"class":44},"Meyer Children's Hospital IRCCS",2,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":57,"phases":210,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":236},"100624563","premabiom-metatranscriptomics-of-the-respiratory-microbiome-to-predict-the-occurrence-of-bronchopulmonary-dysplasia-in-preterm-infants-100624563","NCT07411261","PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants","PremaBiom","Inclusion Criteria:\n\n* Preterm infants with gestational age at birth lower than 32 gestational weeks and 6 days.\n* Hospital stay in one of the participant neonatal care units\n* Infants covered by the social security system of at least one of their parents\n* Whose parents have been informed about the study and agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Palliative care only\n* Lack of parental consent\n* Parents who are minors or under legal protection (guardianship, conservatorship, judicial protection)\n* Parents who do not speak French","72 Hours",{"count":209,"type":22},270,[59],"The goal of this clinical trial is to understand the impact of respiratory microbiome maturation in respiratory health of preterm infants under 32 gestational weeks. The main questions it aims to answer are:\n\n* What is the role of microbiome maturation in respiratory health (development of bronchopulmonary dysplasia, childhood asthma and viral respiratory infections) of preterm infants ?\n* Which environmental or health factors are involved in the maturation of the respiratory microbiome ?\n\nParticipants will undergo follow-up from birth until 3 years of corrected age including nasal swabs, stool samples, and for some of them blood and milk sample.",[213,214,27,215,216],"Bronchopulmonary Dysplasia","Preterm Infant Development","Bronchiolitis","Viral Respiratory Tract Infections",[218,219,220,65,221,222,223,224,225,226,227],"respiratory microbiome","bronchopulmonary dysplasia","Prematurity","bronchiolitis","inflammation","inate immunity","respiratory tract infections","dysbiosis","personalized medicine","metatranscriptomics","2026-02-11",{"date":190,"type":37},{"date":231,"type":22},"2026-03",{"date":233,"type":22},"2031-03",{"name":235,"class":44},"University Hospital, Caen",6,{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":18,"minAge":151,"maxAge":54,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":45},"100602907","remote-monitoring-of-asthma-in-children-and-young-people-100602907","NCT07129616","Remote Monitoring of Asthma in Children and Young People","Remote Monitoring of Asthma in Children and Young People - Reducing Risk of Asthma Attack Using a Connected Patient Approach","Inclusion Criteria:\n\n* Children and Young People with a diagnosis of asthma (coded as asthma or suspected asthma) or a prescription of inhaled corticosteroid in the prior 2 years.\n\nExclusion Criteria:\n\n* Alternative non-asthma diagnosis that would require inhaled steroid\n* cystic fibrosis\n* bronchiectasis\n* primary ciliary dyskinaesia",{"count":245,"type":22},900,"The objective of this study is to determine whether healthcare data and remotely collected patient data can accurately predict asthma attacks in children and young people aged 5-17 years. The main outcome is:\n\nwhen using this new system, is there a reduction in asthma attacks compared with a historic average.\n\nThe whole population of children and young people with asthma will have routine healthcare data monitored, with a subset of people with high risk asthma asked to participate in a more detail study involving remotely monitored data.",[27,248,249,250,251],"Asthma Attack","Remote Monitoring","Risk Assessment","Machine Learning",[253,254],"asthma attack risk reduction","remote monitoring","2026-01-20",{"date":257,"type":37},"2026-01-22",{"date":259,"type":37},"2025-11-20",{"date":261,"type":22},"2027-03-01",{"name":263,"class":44},"University of Edinburgh",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":18,"minAge":128,"maxAge":54,"enrollmentInfo":271,"targetDuration":4,"studyType":57,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100620978","effectiveness-of-an-educational-intervention-on-asthmatic-children-in-inhaled-technique-and-adherence-100620978","NCT07364643","Effectiveness of an Educational Intervention on Asthmatic Children in Inhaled Technique and Adherence.","Assessment of Asthma Management in Children Over 6 Years of Age and Their Caregivers. Implications for the Implementation of the SMART Strategy in Pediatrics.","Inclusion Criteria:\n\n* Clinical diagnosis of asthma.\n* Prescribed treatment with inhaled corticosteroid.\n* First-degree relative of the patient.\n\nExclusion Criteria:\n\n. Inability to understand Spanish.",{"count":272,"type":22},428,[59],"The goal of this study is to see if a short educational session and demonstration by a nurse can help asthmatic children (6-17 years-old), under hospital control, to manage their asthma better, to use their inhaler correctly, and to know when it should be used.\n\nThe main question it aims to answer is how much improvement is reached on asthma self-management. The comparison group is the same group. Researchers will compare results before and after educational intervention.",[27],[277,278,279,280],"inhaler technique","treatment adherence","asthma self-management","nursing intervention","2026-01-16",{"date":283,"type":37},"2026-01-23",{"date":285,"type":22},"2026-01",{"date":287,"type":22},"2027-01",{"name":289,"class":44},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":45},"100617324","the-effectiveness-of-early-immunisation-with-nirsevimab-on-preschool-wheezing-in-france-based-on-an-analysis-of-data-from-the-french-health-system-database-100617324","NCT07317141","The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.","Effectiveness of Early Immunization With Nirsevimab on Preschool Wheezing in France","INSPIRATION","Inclusion Criteria:\n\n* \\- Exposed group of children: all children born between 06\u002F02\u002F2023 and 31\u002F01\u002F2024 and who had received nirsevimab before 6 or 12 months of age depending on the outcomes that will be studied.\n* Unexposed group of children: all children born between 06\u002F02\u002F2023 and 31\u002F01\u002F2024 and who did not receive nirsevimab\n\nExclusion Criteria:\n\n* \\- Infants born in Overseas Departments and Territories (Guadeloupe, Martinique, Guyana, La Réunion, Mayotte, Saint-Pierre-et-Miquelon, French Polynesia, Nouvelle-Calédonie, Wallis-et-Futuna, French Southern and Antarctic Lands, Clipperton island)\n* Same-sex twins, as they cannot be differentiated in the French Medicalization of Information Systems Program (PMSI)\n* Infants born between 06\u002F02\u002F2023 and 31\u002F01\u002F2024 in a maternity unit that has not reported data on the immunization with nirsevimab\n* Infants whose mother had been vaccinated against RSV during pregnancy\n* Infants who received palivizumab immunization\n* Date of nirsevimab immunization not provided\n* Infants hospitalized for wheezing or RSV+ lower respiratory tract infection before receiving nirsevimab\n* Infants who were immunized after 12 months of age for outcomes collected between 2 and 6 years old\n* Infants who were immunized after 6 months of age for outcomes collected during the second year of life","1 Year",{"count":300,"type":22},218000,"Early respiratory syncytial virus (RSV) bronchiolitis is a well-known contributing factor of mid- and long-term respiratory sequelae in children such as recurrent lower tract respiratory infections (LRTIs), preschool wheezing (PW) or decreased lung function at older ages.\n\nNirsevimab, a monoclonal antibody against RSV with enhanced neutralizing activity and a prolonged half-life, has shown great potential in reducing short term outcomes such as hospitalization for RSV associated bronchiolitis (estimated adjusted effectiveness against hospitalization to 83.0% (95%CI: 73.4 to 89.2). Other countries that have been using nirsevimab almost exhaustively have reported similar results such as in Galicia.\n\nHowever, prevention of RSV LRTI or delay RSV infection early in life has not been investigated on respiratory manifestations such early wheezing in infancy (ie before 2 years of age) and recurrent wheezing in preschool period (ie between 2 and 6 years old).\n\nSome recent data have shown that nirsevimab was associated with a reduction of wheezing in the year following its administration (HR: 0.73; 95% CI, 0.58-0.93). Other data have shown that not being infected by RSV during the infancy was associated with 26% lower risk of 5-year current asthma than being infected (5) giving good rational for preventive strategies against RSV to impact midterm respiratory outcomes such as PW and then asthma.\n\nOngoing observational cohort studies will help investigate the question of mid-term effects, but they will come with a high costs and risk of attrition. Administrative national health claims database could prove to be useful and complementary by studying these types of real world outcomes across lives of children that have been immunized by nirsevimab as shown recently.\n\nTherefore, the investigators aim to study the impact of early nirsevimab administration on wheezing manifestations occurring in infancy and beyond during the preschool years.\n\nOur primary objective is to see if nirsevimab administration during the first six months of life has an impact on hospitalization for wheezing episodes during the second year of life, based on the hypothesis that infants who had received nirsevimab have reduced hospitalization for wheezing during their second year of infancy.",[303,304,27],"Infant Wheeze","Preschool Age Children",[306,307,31,308],"nirsevimab","wheezing disease","preschoolers","2026-01-06",{"date":311,"type":37},"2026-01-08",{"date":313,"type":22},"2026-01-01",{"date":315,"type":22},"2029-06-01",{"name":317,"class":44},"Hospices Civils de Lyon"]